There's always the possibility that outstanding shares will be sold into strength but fund managers do buy on the open market and being traded on the Nasdaq would really help facilitate the chances of that happening. There are hordes of investment managers with a wide range of assets under management in the US and Canada, from the tens of millions to the trillions.
Not to say that Nasdaq will be a panacea: volatility could increase, we could attract short sellers or be more susceptible to macro forces and there are plenty of relatively thinly traded Nasdaq stocks, but AMEUF is essentially unknown currently so being on Nasdaq would definitely offer the potential to bring in new investors.
Any small clinical-stage company will have to cut the pie into smaller pieces one way or another, whether it's only with dilution or portioning off a percentage of future revenue to a commercialization partner or taking buyout money upfront and sacrificing future gains. It's all about how attractive the market cap is balanced against a reasonable estimate of those possibilities. I think we are currently well within bargain status in that balance.
Add to My Watchlist
What is My Watchlist?
